Antiangiogenic therapies for malignant pleural mesothelioma

Frontiers in Bioscience

Volumn 16, Issue 2, 2011, Pages 740-748

  Yano, Seiji ^a   Li, Qi ^a   Wang, Wei ^a   Yamada, Tadaaki ^a   Takeuchi, Shinji ^a   Nakataki, Emiko ^b   Ogino, Hirokazu ^b   Goto, Hisatsugu ^b   Nishioka, Yasuhiko ^b   Sone, Saburo ^b  

^a KANAZAWA UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Angiogenesis; FGF 2; Mesothelioma; Orthotopic model; Pleural effusion; Review; VEGF; VEGFR

Indexed keywords

4 (3 CHLORO 4 (N' CYCLOPROPYLUREIDO)PHENOXY) 7 METHOXYQUINOLINE 6 CARBOXAMIDE; 4-(3-CHLORO-4-(N'-CYCLOPROPYLUREIDO)PHENOXY)-7-METHOXYQUINOLINE-6-CARBOXAMIDE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBANILAMIDE DERIVATIVE; MONOCLONAL ANTIBODY; N (4 BROMO 2 FLUOROPHENYL) 6 METHOXY 7 ((1 METHYLPIPERIDIN 4 YL)METHOXY)QUINAZOLIN 4 AMINE; N-(4-BROMO-2-FLUOROPHENYL)-6-METHOXY-7-((1-METHYLPIPERIDIN-4-YL)METHOXY)QUINAZOLIN-4-AMINE; PIPERIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; QUINOLINE DERIVATIVE; VASCULOTROPIN;

ANIMAL; BIOSYNTHESIS; CANCER TRANSPLANTATION; DISEASE MODEL; HUMAN; MESOTHELIOMA; METABOLISM; MOUSE; MOUSE MUTANT; NEOVASCULARIZATION (PATHOLOGY); PLEURA EFFUSION; PLEURA TUMOR; REVIEW; THORACIC CAVITY; TUMOR CELL LINE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; HUMANS; MESOTHELIOMA; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PHENYLUREA COMPOUNDS; PIPERIDINES; PLEURAL EFFUSION, MALIGNANT; PLEURAL NEOPLASMS; QUINAZOLINES; QUINOLINES; THORACIC CAVITY; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 79955020053     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3716     Document Type: Article

References (45)

1. Light R.W. Pleural diseases, fourth edition. Lippomcott Willianms & Wilkins, Philadelphia. 92001)
2. V.C. Broaddus. : Asbestos, the mesothelial cell and malignancy: a matter of life or death. Am J Respir Cell Mol Biol. 17, 657-659 (1997) (Pubitemid 127348656)
3. K. Morinaga, T. Kishimoto, M. Sakatani, M. Akira, K. Yokoyama, Y. Sera. : Asbestos-related lung cancer and mesothelioma in Japan. Industrial Health 39, 65-74 (2001) (Pubitemid 32452453)
4. A. Dufresne, R. Bégin R, A. Churg, S. Masse. Mineral fiber content of lungs in patients with mesothelioma seeking compensation in Quebec. Am J Respir Crit Care Med. 153:711-718 (1996)
5. Y. Sekido: Genomic abnormalities and signal transduction dysregulation in malignant mesothelioma cells. Cancer Sci. 101:1-6 (2010)
6. J. Folkman : Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186 (1971)
7. L. Hlatky, P. Hahnfeldt, J. Folkman : Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 94: 883-893 (2002) (Pubitemid 34778087)
8. Y. Ohta, V. Shridhar, R.K. Bright, G.P. Kalemkerian, W. Du, M. Carbone, Y. Watanabe, H.I. Pass : VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer 81: 54-61 (1999) (Pubitemid 29415491)
9. S. Kumar-Singh, J. Weyler, M.J. Martin, P.B. Vermeulen, E. Van Marck : Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and-2, and TGF beta expression. J Pathol 189: 72-78 (1999) (Pubitemid 29406822)
10. E. Tolnay, C. Kuhnen, T. Wiethege, J.E. König, B. Voss, K.M. Müller : Hepatocyte growth factor/scatter factor and its receptor c-Met are overexpressed and associated with an increased microvessel density in malignant pleural mesothelioma. J Cancer Res Clin Oncol. 124: 291-296 (1998) (Pubitemid 28332909)
11. S. Yano, H. Shinohara, R.S. Herbst, H. Kuniyasu, C.D. Bucana, L.M. Ellis, I.J. Fidler : Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells. Am J Pathol 157: 1893-1903 (2000)
12. D.R. Senger, S.J. Galli, A.M. Dvorak, C.A. Perruzzi, V.S. Harvey, H.F. Dvorak : Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219: 983-985 (1983)
13. I.J. Fidler: Orthotopic implantation of human colon carcinomas into nude mice provides a valuable model for the biology and therapy of metastasis. Cancer Metastasis Rev 10:229-243 (1991)
14. E. Nakataki, S. Yano, Y. Matsumori, H. Goto, S. Kakiuchi, H. Muguruma, Y. Bando, H. Uehara, H. Hamada, K. Kito, A. Yokoyama, S. Sone : Novel orthotopic implantation model of human malignant pleural mesothelioma (EHMES-10 cells) highly expressing vascular endothelial growth factor and its receptor. Cancer Sci 97: 183-191 (2006)
15. Q. Li, S. Yano, H. Ogino, W. Wang, H. Uehara, Y. Nishioka, S. Sone : The therapeutic efficacy of anti vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice. Clin Cancer Res 13: 5918-5925 (2007) (Pubitemid 47583920)
16. K. Ikuta, S. Yano, V.T. Trung, M. Hanibuchi, H. Goto, Q. Li, W. Wang, T. Yamada, H. Ogino,S. Kakiuchi, H. Uehara, Y. Sekido, T. Uenaka, Y. Nishioka, S. Sone. E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles. Clin Cancer Res. 15:7229-7237 (2009)
17. H. Yanagawa, E. Takeuchi, Y. Suzuki, Y. Ohmoto, H. Bando, S. Sone : Vascular endothelial growth factor in malignant pleural effusion associated with lung cancer. Cancer Immunol Immunother. 48:396-400 (1999) (Pubitemid 29461393)
18. B.K. Zebrowski, S. Yano, W. Liu, R.M. Shaheen, D.J. Hicklin, J.B. Putnam Jr, L.M. Ellis : Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin Cancer Res. 5:3364-3368 (1999)
19. D.R. Senger, S.J. Galli, A.M. Dvorak, C.A. Perruzzi, V.S. Harvey, H.F. Dvorak : Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 219:983-985 (1983)
20. N. Ferrara, T. Davis-Smyth. The biology of vascular endothelial growth factor. Endocr Rev 18: 4-25 (1997) (Pubitemid 27076453)
21. L.G. Presta, H. Chen, S.J. O'Connor, V. Chisholm, Y.G. Meng, L. Krummen, M. Winkler, N. Ferrara : Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57: 4593-4599 (1997) (Pubitemid 27441066)
22. H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, W. Heim, J. Berlin, A. Baron, S. Griffing, E. Holmgren, N. Ferrara, G. Fyfe, B. Rogers, R. Ross, F. Kabbinavar : Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342 (2004) (Pubitemid 38702844)
23. D.H.Johnson, L. Fehrenbacher, W.F. Novotny, R.S. Herbst, J.J. D.M. Jablons, C.J. Langer, R.F. DeVore 3rd, J. Gaudreault, L.A. Damico, E. Holmgren, F. Kabbinavar : Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22: 2184-2191 (2004) (Pubitemid 41095154)
24. J.C. Yang, L. Haworth, R.M. Sherry, P. Hwu, D.J. Schwartzentruber, S.L. Topalian, S.M. Steinberg, H.X. Chen, S.A. Rosenberg : A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349: 427-434 (2003) (Pubitemid 36910021)
25. W.D. Fox, B. Higgins, K.M. Maiese, M. Drobnjak, C. Cordon-Cardo, H.I. Scher, D.B. Agus : Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer. Clin Cancer Res 8: 3226-3231 (2002) (Pubitemid 35155035)
26. M. Joerger, A. Omlin, T. Cerny, M. Früh: The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action. Curr Drug Targets 11:37-47 (2010)
27. N.J. Vogelzang, J.J. Rusthoven, J. Symanowski, C. Denham, E. Kaukel, P. Ruffie, U. Gatzemeier, M. Boyer, S. Emri, C. Manegold, C. Niyikiza,P. Paoletti : Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21: 2636-2644 (2003) (Pubitemid 46606305)
28. R.K. Jain: Normalizing tumor vasculature with ntiangiogenic therapy: a new paradigm for combination therapy. Nat Med 7: 987-9 (2001) (Pubitemid 32937367)
29. M.A. Versnel, L. Claesson-Welsh, A. Hammacher, M.J. Bouts, T.H. van der Kwast, A. Eriksson, R. Willemsen, S.M. Weima, H.C. Hoogsteden, A. Hagemeijer, et al. :Human malignant mesothelioma cell lines express PDGF beta-receptors whereas cultured normal mesothelial cells express predominantly PDGF alpha-receptors. Oncogene. 6:2005-2011 (1991) (Pubitemid 21924040)
30. T.C. Lee, Y. Zhang, C. Aston, R. Hintz, J. Jagirdar, M.A. Perle, M. Burt, W.N. Rom : Normal human mesothelial cells and mesothelioma cell lines express insulin-like growth factor I and associated molecules. Cancer Res. 53:2858-2864 (1993) (Pubitemid 23180528)
31. I.A. Morocz, D. Schmitter, B. Lauber, R.A. Stahel : Autocrine stimulation of a human lung mesothelioma cell line is mediated through the transforming growth factor alpha/epidermal growth factor receptor mitogenic pathway. Br J Cancer. 70:850-856 (1994) (Pubitemid 24331076)
32. P.A. Zucali, G. Giaccone : Biology and management of malignant pleural mesothelioma. Eur J Cancer. 42:2706-2714 (2006) (Pubitemid 44584672)
33. S.R. Wedge, D.J. Ogilvie, M. Dukes, J. Kendrew, R. Chester, J.A. Jackson, S.J. Boffey, P.J. Valentine, J.O. Curwen, H.L. Musgrove, G.A. Graham, G.D. Hughes, A.P. Thomas, E.S. Stokes, B. Curry, G.H. Richmond, P.F. Wadsworth, A.L. Bigley, L.F. Hennequin : ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62:4645-4655 (2002)
34. F. Ciardiello, R. Caputo, V. Damiano, R. Caputo, T. Troiani, D. Vitagliano, F. Carlomagno, B.M. Veneziani, G. Fontanini, A.R. Bianco, G. Tortora : Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 9:1546-1556 (2003) (Pubitemid 36418413)
35. F. Carlomagno, D. Vitagliano, T. Guida, F. Ciardiello, G. Tortora, G. Vecchio, A.J. Ryan, G. Fontanini, A. Fusco, M. Santoro. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 62:7284-7290 (2002) (Pubitemid 36025251)
36. S. Yano, H. Muguruma, Y. Matsumori, H. Goto, E. Nakataki, N. Edakuni, H. Tomimoto, S. Kakiuchi, A. Yamamoto, H. Uehara, A. Ryan, S. Sone. Antitumor vascular strategy for controlling experimental metastatic spread of human small-cell lung cancer cells with ZD6474 in natural killer cell-depleted severe combined immunodeficient mice. Clin Cancer Res 11:8789-8798 (2005) (Pubitemid 43005930)
37. Y. Matsumori, S. Yano, H. Goto, E. Nakataki, S.R. Wedge, A.J. Ryan, S. Sone : ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model. Oncol Res 16:15-26 (2006) (Pubitemid 44195046)
38. R.B. Natale, D. Bodkin, R. Govindan, B.G. Sleckman, N.A. Rizvi, A. Capó, P. Germonpré, W.E. Eberhardt, P.K. Stockman, S.J. Kennedy, M. Ranson : Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study. J Clin Oncol. 27:2523-2529 (2009)
39. J.V. Heymach, B.E. Johnson, D. Prager, E. Csada, J. Roubec, M. Pesek, I. Spásová, C.P. Belani, I. Bodrogi, S. Gadgeel, S.J. Kennedy, J. Hou, R.S. Herbst : Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol. 25:4270-4277 (2007) (Pubitemid 47548567)
40. K. Kiura, K. Nakagawa, T. Shinkai, K. Eguchi, Y. Ohe, N. Yamamoto, M. Tsuboi, S. Yokota, T. Seto, H. Jiang, K. Nishio, N. Saijo, M. Fukuoka : A randomized, doubleblind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer. J Thorac Oncol. 3:386-393 (2008) (Pubitemid 351489479)
41. H. Ogino, S. Yano, S. Kakiuchi, T. Yamada, K. Ikuta, E. Nakataki, H. Goto, M. Hanibuchi, Y. Nishioka, A. Ryan, S. Sone : Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement. Cancer Lett. 265:55-66 (2008)
42. J. Matsui, Y. Yamamoto, Y. Funahashi, A. Tsuruoka, T. Watanabe, T. Wakabayashi, T. Uenaka, M. Asada : E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer 122: 664-671 (2008) (Pubitemid 350308963)
43. J. Matsui, Y. Funahashi, T. Uenaka, T. Watanabe, A. Tsuruoka, M. Asada : Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 14: 5459-5465 (2008)
44. K. Yamada, N. Yamamoto, Y. Yamada, Y. Fujiwara, H. Nokihara, T. Hirata, F. Koizumi, K. Nishio, N. Koyama, T. Tamura : Phase I dose escalation study and biomarker analysis of E7080 in patients with advanced solid tumors. ASCO 2008 Abst 3527 handout (2008).
45. H. Glen, D. Boss, R. Morrison, M. Roelvink, J. Wanders, A. Mazur, A. Gupta, A. Das, T.R.J. Evans, J.H.M. Schellens : A phase I dose escalation and pharmacokinetic study of E7080, a small molecule tyrosine kinase inhibitor, in patients with advanced malignancies. ASCO 2008, Abst 3526 handout (2008)